| long2017 | R Documentation |
Data stem from a double-blind, placebo-controlled phase 3 trial where n=870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations were randomly assigned to receive oral Dabrafenib plus Trametinib (combination therapy, 438 patients) or two matched placebo tablets (432 patients) for 12 months.
long2017
A data frame with 870 rows and 4 variables:
artificially generated patient ID
Time to relapse-free survival in months
Status of observation, encoded as 0 for right-censoring vs 1 for RFS-event
Treatment group: Dabrafenib+Trametinib vs Placebo
Unfortunately, the data set of the clinical trial is not publicly available. Instead, the data were digitized by Sean Devlin based on the published survival plot (see Fig 1A in the original publication of the trial results). Therefore, the data given here do not claim to be a 100% faithful representation of the clinical trial. Some deviations are to be expected.
Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017;377(19):1813-1823. doi:10.1056/NEJMoa1708539
Devlin SM and O'Quigley J, The nph2ph-transform: applications to the statistical analysis of completed clinical trials, arXiv:2407.18905, 2024. doi:10.48550/arXiv.2407.18905.
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.